Two recently released studies indicate that the MultiOmyx Hodgkin’s Lymphoma profile from Clarient Diagnostic Services, a GE Healthcare company, and an investigational profile for breast care may improve assessment of both diseases in certain patient subsets.

“These data show how using MultiOmyx can empower pathologists and oncologists to gain a much deeper understanding of what can be seen in a tumor, on a slide, region of interest, or at a cellular level in a variety of cancers,” said Christine Kuslich, chief scientific officer for GE Healthcare Life Sciences. “The ability to multiplex and visualize the contextual relationship between key proteins in the same cells from a single piece of tissue will help investigators answer questions they previously did not have the tools for. We can now investigate complex protein networks without disrupting their cellular relationship to the surrounding tissue.”

MultiOmyx assesses multiple proteins in a tissue section at a single-cell level, while preserving tissue context. “Traditional pathology uses multiple slices from paraffin-fixed tumor samples and examines them slide by slide, which is less efficient and effective,” said Kenneth Bloom, M.D., chief medical officer of Clarient Diagnostic Services Inc. “Using a single slide may save time overall, uses significantly less tissue, and may provide a more consistent result. Since different parts of a tumor sample can act differently and because less tissue is required, pathologists can perform accurate and broad tumor analyses, while eliminating today’s need to prioritize tests due to limited tissue availability.”

For more information, visit GE Healthcare